本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Summit Therapeutics PLC

17.30
-0.1000-0.57%
盤後17.28-0.0200-0.12%19:53 EDT
成交量:608.79萬
成交額:1.06億
市值:138.01億
市盈率:-15.48
高:17.75
開:17.50
低:17.11
收:17.40
52周最高:29.23
52周最低:12.07
股本:7.98億
流通股本:1.52億
量比:1.16
換手率:4.00%
股息:- -
股息率:- -
每股收益(TTM):-1.1177
每股收益(LYR):-1.4439
淨資產收益率:-192.50%
總資產收益率:-101.61%
市淨率:21.91
市盈率(LYR):-11.98

資料載入中...

2020/09/28

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2020/09/18

交易所摘牌聲明

25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2020/06/17

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2020/05/21

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2020/05/15

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2020/04/30

年度報告

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/03/26

超過5%披露

[Amend] General statement of acquisition of beneficial ownership
2020/02/26

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/06

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/27

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/23

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/23

超過5%披露

General statement of acquisition of beneficial ownership
2020/01/16

超過5%披露

[Amend] General statement of acquisition of beneficial ownership
2019/12/27

超過5%披露

[Amend] General statement of acquisition of beneficial ownership
2019/12/26

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/23

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/17

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/10

超過5%披露

[Amend] General statement of acquisition of beneficial ownership
2019/12/06

非美公司披露報告

[Amend] Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/06

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]